This is an outdated version published on 2020-07-15. Read the most recent version.

Cardiology News / Recent Literature Review / Second Quarter 2020

Cardiology News


  • Antonis S Manolis Third Department of Cardiology, Athens University School of Medicine, Athens, Greece
  • Hector Anninos Athens University School of Medicine


Cardiology News / Recent Literature Review / Second Quarter 2020

Rhythmos 2020;15(3):55-63.  

ESC Meeting/Digital Experience: 29/8-1/9/2020

TCT/ Virtual Event: 14-18/10/2020

HCS/Panhellenic (41st) Congress of Cardiology: Athens, 22-24/10/2020

AHA Meeting 2020: cancelled

ACC Meeting: Atlanta, 20-22/3/2021

EHRA Meeting: Barcelona, 28-30/3/2021

Women Have a Higher Risk of MACE and Ischemia-Driven Target Lesion Revascularization (ID-TLR) Compared With Men at 5 Years Post-PCI

Among 32,877 patients, 9,141 (27.8%) were women who were older and had higher body mass index, more frequent hypertension and diabetes, and less frequent history of surgical or percutaneous revascularization compared with men. Lesions in women had smaller reference vessel diameter and shorter lesion length. At 5 years, women had a higher rate of MACE (18.9% vs 17.7%; p=0.003), all-cause death (10.4% vs 8.7%; p=0.0008), cardiac death (4.9% vs 4.0%; p=0.003) and ID-TLR (10.9% vs 10.2%; p=0.02) compared with men. By multivariable analysis, female sex was an independent predictor of MACE (hazard ratio [HR:]: 1.14; p=0.04) and ID-TLR (HR: 1.23; p=0.009) but not all-cause death (HR: 0.91; p=0.30) or cardiac death (HR: 0.97; p=0.85) (Kosmidou I et al, J Am Coll Cardiol 2020; 75:1631-40).

PARAGON-HF: Baseline and Mean Achieved Systolic Blood Pressure (SBP) of 120-129 mmHg Identified the Lowest Risk Patients With Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/ Valsartan

Among 4,795 trial participants (age 73 ± 8 years, 52% women), multivariable analysis indicated that baseline and mean achieved SBP of 120-129 mmHg demonstrated the lowest risk for all outcomes. Sacubitril/valsartan reduced SBP by 5.2 mmHg compared with valsartan at 4 weeks, which was not modified by baseline SBP. However, sacubitril/valsartan reduced SBP more in women (6.3 mmHg) than men (4 mmHg) (interaction p=0.005). Change in SBP was directly associated with change in NT-proBNP (p<0.001) but not symptom score (p=0.40) (Selvaraj S et al, J Am Coll Cardiol 2020; 75:1644-56)... (excerpt)







Cardiology News